Eli Lilly Grants Early Access to Revolutionary Weight Loss Drug, Retatrutide

In a significant breakthrough for the weight loss and wellness industry, Eli Lilly (NYSE: LLY) announced on August 3, 2026, that it would extend early access to retatrutide—its potent, yet-to-be-approved obesity drug—to a wider patient group before it secures U.S. FDA approval.

Retatrutide operates by concurrently targeting three hormonal pathways—GLP-1, GIP, and glucagon. This makes it more potent than Lilly’s current weight loss drug, Zepbound (which targets two pathways), and Novo Nordisk’s Wegovy (which targets one). In the most scrutinized late-stage trial, participants who received the highest 12 mg dose experienced an average weight loss of 28.3% over 80 weeks. These results are on par with those of bariatric surgery. A separate trial involving adults with severe obesity and established heart disease reported an average weight loss of 22.6%.

To qualify for early access, patients must be 18 years or older, have refractory obesity despite tolerating the highest approved dose of obesity therapy, and have at least two serious or life-threatening obesity-related complications. Lilly is currently reviewing requests from healthcare providers and plans to apply for FDA approval of retatrutide in the first quarter of 2027.

Source: Quartz – Eli Lilly expanding early access to retatrutide weight loss drug